Two Sigma Advisers
AKCA

Two Sigma Advisers’s Akcea Therapeutics Inc AKCA Stock Holding History

Two Sigma Advisers’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,000
Closed -$362K – 2496
2018
Q4 		$362K Sell
12,000
-2,200
-15% -$61.7K ﹤0.01% 1899
2018
Q3 		$497K Buy
+14,200
New +$430K ﹤0.01% 1801

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Two Sigma Advisers's AKCA Position: Q1 2019 in Review

Two Sigma Advisers sold out of Akcea Therapeutics Inc (AKCA) in Q1 2019, closing a stake of 12,000 shares — an estimated $362K sold.

Two Sigma Advisers first reported a position in AKCA in Q3 2018 and held it in 2 quarters. The position peaked at $497K in Q3 2018. 74 funds tracked by Wall St. Rank hold AKCA as of Q1 2019.

  • Two Sigma Advisers reported no remaining Akcea Therapeutics Inc position as of Q1 2019 after selling out during the quarter.
  • Two Sigma Advisers sold 12,000 Akcea Therapeutics Inc shares in Q1 2019, an estimated $362K.
  • Two Sigma Advisers first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 2 quarters.
  • Two Sigma Advisers's Akcea Therapeutics Inc position peaked at $497K in Q3 2018.
  • 74 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2019.

Based on Two Sigma Advisers's 13F filing for Q1 2019, filed 15 May 2019.